[gdpawel]

Sarah

I can only add to your statement by deleting the word "may." We have ways to tell what will work and what won't. We just have to overcome the resistance to it by an entrenched cancer establishment. And I agree, the future looks so promising, but that future is already happening. It just has to be revealed.

The selection of a chemotherapy regimen for individual tumors is normally based on histology, clinical characteristics of the patient and retrospective evidence from randomized clinical trials.

However, patients with the same tumor histotype, especially in solid malignancies, often respond differently to the same chemotherapy regimen due to heterogeneity of cancer.

Systems Biology is the field of biology that examines biological processes in the context of an entire system of processes within a cell or organism.

Systems biology utilizes a combination of biochemistry, proteomics, genomics, metabolomics and bioinformatics to better understand the contribution of each element of the system to the whole.

This is what pioneers of cell function analysis (functional profiling) are doing with cancer treatment.

Despite knowledge of such heterogeneity, chemotherapy is still largely empirically planned (trial-and-error), and the acquisition of information for tailored therapy has consequently become a priority in the management of cancer patients today.

The chance that you are the median patient in a randomized clinical trial is quite small. Would you want to gamble with your health based on "odds" that you are just like the median patient in some population of patients tested in a clinical trial?

There is a large and growing volume of clinical data that establishes the predictive validity of the functional profiling platform. Both solid and hematologic tumors have been evaluated with statistically significant results.

Greg